Steadymed Ltd (NASDAQ:STDY) will exhibit a poster providing an overview of its development of Trevyent®, its lead drug product candidate for the treatment of Pulmonary Arterial Hypertension (PAH), and of its PatchPump technology at the Parenteral Drug Association Conference in Huntington Beach, California.  The poster includes data relating to the Company’s Registration Stability Lot program and ongoing Development Stability Program for Trevyent. A copy of the poster to be presented at the conference is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.